These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 16378532)

  • 1. The biggest bang for the buck or bigger bucks for the bang: the fallacy of the cost-effectiveness threshold.
    Birch S; Gafni A
    J Health Serv Res Policy; 2006 Jan; 11(1):46-51. PubMed ID: 16378532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda.
    Gafni A; Birch S
    Soc Sci Med; 2006 May; 62(9):2091-100. PubMed ID: 16325975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions.
    Adang E; Voordijk L; Jan van der Wilt G; Ament A
    Health Policy; 2005 Oct; 74(2):146-56. PubMed ID: 16153475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of group psychotherapy for depression in Uganda.
    Siskind D; Baingana F; Kim J
    J Ment Health Policy Econ; 2008 Sep; 11(3):127-33. PubMed ID: 18806302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of cost effectiveness analysis in health care evaluation.
    Atherly A; Culler SD; Becker ER
    Q J Nucl Med; 2000 Jun; 44(2):112-20. PubMed ID: 10967622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions.
    Cleemput I; Neyt M; Thiry N; De Laet C; Leys M
    Int J Technol Assess Health Care; 2011 Jan; 27(1):71-6. PubMed ID: 21262069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of age on cost-effectiveness ratios and its control in decision making.
    Baltussen R; Leidl R; Ament A
    Health Econ; 1996; 5(3):227-39. PubMed ID: 8817297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Philosophical concerns regarding cost-effectiveness analyses.
    Weiner BK
    Med Hypotheses; 2010 Feb; 74(2):383-6. PubMed ID: 19651478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costing and perspective in published cost-effectiveness analysis.
    Neumann PJ
    Med Care; 2009 Jul; 47(7 Suppl 1):S28-32. PubMed ID: 19536023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis.
    Melnikow J; Birch S; Slee C; McCarthy TJ; Helms LJ; Kuppermann M
    Med Care; 2008 Sep; 46(9):946-53. PubMed ID: 18725849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
    Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
    J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shoulder acute pain in primary health care: is retraining GPs effective? The SAPPHIRE randomized trial: a cost-effectiveness analysis.
    McKenna C; Bojke L; Manca A; Adebajo A; Dickson J; Helliwell P; Morton V; Russell I; Torgerson D; Watson J
    Rheumatology (Oxford); 2009 May; 48(5):558-63. PubMed ID: 19258378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The costs and benefits of enhanced depression care to employers.
    Wang PS; Patrick A; Avorn J; Azocar F; Ludman E; McCulloch J; Simon G; Kessler R
    Arch Gen Psychiatry; 2006 Dec; 63(12):1345-53. PubMed ID: 17146009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An opportunity cost approach to sample size calculation in cost-effectiveness analysis.
    Gafni A; Walter SD; Birch S; Sendi P
    Health Econ; 2008 Jan; 17(1):99-107. PubMed ID: 17497751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Medical economy--a new challenge for physicians].
    Beeler I; Szucs TD
    Praxis (Bern 1994); 2000 May; 89(20):861-7. PubMed ID: 10865509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does Medicare have an implicit cost-effectiveness threshold?
    Chambers JD; Neumann PJ; Buxton MJ
    Med Decis Making; 2010; 30(4):E14-27. PubMed ID: 20551473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generalised cost-effectiveness analysis: an aid to decision making in health.
    Hutubessy RC; Baltussen RM; Torres-Edejer TT; Evans DB
    Appl Health Econ Health Policy; 2002; 1(2):89-95. PubMed ID: 14619255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.
    Xie F; Blackhouse G; Assasi N; Campbell K; Levin M; Bowen J; Tarride JE; Pi D; Goeree R
    Clin Ther; 2009 May; 31(5):1082-91; discussion 1066-8. PubMed ID: 19539109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness in healthcare: complexity of the equation.
    Archambault A
    J Can Diet Assoc; 1988; 49(2):80-5. PubMed ID: 10312528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality-adjusted life years: how useful in medico economic studies.
    Brauer CA; Neumann PJ
    Fundam Clin Pharmacol; 2005 Dec; 19(6):603-7. PubMed ID: 16313271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.